LncRNA Information
ID EL0127 Name ADAMTS9-AS2 Aliases N/A
Species Homo sapiens Chromosome 3 Start site 64684870
End site 65011468 Chain plus Exon NO. 6
Assembly GRCh38.p13 Class antisense NCBI accession NR_038264
Ensembl ENSG00000241684 Sequence NR_038264 Peptide-related N/A
CircRNA N/A Exosomal N/A Structure N/A


Disease
Disease Drug/chemo/stress Method Sample Expression pattern Dysfunction type Description PMID
lung cancer qRT-PCR, luciferase reporter, western blot, lung cancer tissues and cell, Tumor xenograft model down-regulated interaction ADAMTS9-AS2, miR-223-3p and TGFBR3 may provide potential targets for the treatment of lung cancer patients. 29707897
salivary adenoid cystic carcinoma knockdown, overexpression, SACC patients with metastasis and SACC-lung metastasis (LM) cells up-regulated interaction Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling 30217729
ovarian cancer ovarian cancer tissues and cell lines down-regulated interaction LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway 30268751
breast cancer qRT-PCR, luciferase reporter gene assay, western blot, Overexpression, mimics, knockdown TAM-resistant BC cell lines down-regulated interaction Low expression of ADAMTS9 AS2 inhibits PTEN expression and enhances tamoxifen resistance through targeting microRNA 130a-5p. 30840279
tongue squamous cell carcinoma luciferase reporter assay, RIP, knockdown, TSCC tissues from patients with lymph node metastasis up-regulated interaction LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. 30970517
colorectal cancer qRT-PCR, Overexpression, knockdown colon cancer cell lines up-regulated interaction The ADAMTS9-AS2/miR-32/PHLPP2 regulatory axis may serve as a potential therapeutic target for CRC. 31144439
clear cell renal cell carcinoma luciferase reporter, RIP, overexpression ccRCC clinical samples and cell lines down-regulated interaction LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis. 31400752
esophageal cancer demethylating agent 5-aza-dc. qRT-PCR, overexpression, knockdown, MSP, RNA pull-down, RIP, ChIP esophageal cancer OE21 cells, nude mice down-regulated interaction Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. 31621118
glioblastoma Temozolomide Resistance RNA pull-down, RIP, overexpression, knockdown, Two anti TMZ GBM cell lines (t98g-r / u118-r), GBM patients with TMZ and culture of cell lines up-regulated interaction Novel Function of lncRNA ADAMTS9-AS2 in Promoting Temozolomide Resistance in Glioblastoma via Upregulating the FUS/MDM2 Ubiquitination Axis. 31632968
glioma qRT-PCR, western blot, knockdown glioma tumor tissue, cell lines (T98G, A172, SNB-19 etc.) down-regulated expression A new tumor suppressor?LncRNA?ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells. 24833086
non-small cell lung cancer microarray, qRT-PCR NSCLC tissue down-regulated expression The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. 25590602
clear cell renal cell carcinoma qRT-PCR clear cell renal cell carcinoma cells down-regulated expression LncRNAs are involved in renal carcinogenesis and decreased lncRNA ENSG00000241684 expression may be an independent adverse prognostic factor in advanced ccRCC patients. 29433989
breast cancer RNA-seq, Knockdown, overexpression, qRT-PCR, 6 invasive ductal carcinoma (IDC) tissues along with paired normal tissue samples, 7 ductal carcinoma situ (DCIS) tissues and 5 apparently normal breast tissues. down-regulated expression Down-regulation of ADAMTS9-AS2 in breast cancer was due to promoter hypermethylation through in vitro silencing experiments and pyrosequencing. 30959550
colorectal cancer microarray, qRT-PCR, overexpression CRC tissues down-regulated expression Overexpression of the long non-coding RNA ADAMTS9-AS2 suppresses colorectal cancer proliferation and metastasis. 31413211
non-small cell lung cancer Microarray, qRT-PCR down-regulated expression Twelve targets were successfully validated by qPCR (upregulated: FEZF1-AS1, LINC01214, LINC00673, PCAT6, NUTM2A-AS1, LINC01929; downregulated: PCAT19, FENDRR, SVIL-AS1, LANCL1-AS1, ADAMTS9-AS2 and LINC00968). All of them were successfully cross validated in the TCGA datasets. 32020063
gastric cancer GC tissues down-regulated expression LncRNA ADAMTS9-AS2 suppresses the proliferation of gastric cancer cells and the tumorigenicity of cancer stem cells through regulating SPOP. 32160650


Function (not disease relevant)
Drug/chemo/stress Methods Sample/condition Expression pattern Dysfunction type Description PMID
microarray,overexpression, human mesenchymal stem cells (hMSCs) up-regulated interaction ADAMTS9-AS2 plays an important role in chondrogenic differentiation as a ceRNA, so that it can be regarded as a therapy target for cartilage repair. 31671346


Interaction
Interaction target Level of interaction Type of interaction Methods Description PMID
CDH3 RNA-DNA regulation RIP, ChIP Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. 31621118
FUS RNA-Protein binding RIP both endogenous and exogenous ADAMTS9-AS2 directly binds to the RRM and Znf_RanBP2 domains of FUS, consequently increasing FUS protein expression. 31632968
miR-130a-5p RNA-RNA binding western blot Dual-luciferase reporter gene assay confirmed the binding condition between ADAMTS9-AS2 and microRNA-130a-5p, showing a negative correlation 30840279
miR-143-3p RNA-RNA binding N/A Overexpression of ADAMTS9-AS2 competitively bound to miR-143-3p that inhibited ITGA6 from miRNA-mediated degradation, and thus it activated the activity of PI3K/Akt and MEK/Erk signaling and facilitated SACC metastasis. 30217729
miR-182-5p RNA-RNA binding N/A ADAMTS9-AS2 functioned as a competing endogenous RNA (ceRNA) for miR-182-5p to promote cell proliferation and invasion. In addition, we revealed that FOXF2 acted as a direct target of miR-182-5p and mediated the effects of ADAMTS9-AS2 on OC cells progression. 30268751
miR-223-3p RNA-RNA binding N/A ADAMTS9-AS2 and TGFBR3 were the direct genes of miR-223-3p. MiR-223-3p promotes proliferation, migration and invasion of lung cancer cells by targeting TGFBR3. 29707897
miR-27a-3p RNA-RNA binding RIP miR-27a-3p was identified as an inhibitory target of ADAMTS9-AS2 31400752
miR-32 RNA-RNA regulation N/A Overexpression of ADAMTS9-AS2 in colon cancer cell lines significantly inhibit ted the miR-32 expression and promoted PHLPP2 expression 31144439
miR-600 RNA-RNA regulation luciferase reporter assay, RIP ADAMTS9-AS2 is a cytoplasmic lncRNA that shares the miRNA response elements (MREs) of miR-600 with EZH2 30970517
miR-942-5p RNA-RNA binding N/A ADAMTS9-AS2 can sponge miR-942-5p to regulate the expression of Scrg1, a transcription factor promoting chondrogenic gene expression. 31671346
RRM RNA-Protein binding RIP both endogenous and exogenous ADAMTS9-AS2 directly binds to the RRM and Znf_RanBP2 domains of FUS, consequently increasing FUS protein expression. 31632968
Display: